Trials / Completed
CompletedNCT00497198
Efficacy and Safety Study of MCI-196 in Patients With Type 2 Diabetes
An Exploratory Study of MCI-196 for Treatment of Type 2 Diabetes in Randomized, Double-Blind, Parallel-Assignment, Placebo-Controlled Manner
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 183 (actual)
- Sponsor
- Tanabe Pharma Corporation · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this study is to evaluate the efficacy of MCI-196 in patients with Type 2 Diabetes based on the changes in blood glucose-related parameters and safety after 12 weeks administration in double-blind, placebo-controlled manner. And in addition, the changes in lipid-related parameters are examined.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MCI-196 | Three tablets of MCI-196 500mg tablet at a time, three times daily, 12 weeks administration (dose in a day: 4500mg) |
| DRUG | Placebo of MCI-196 Tablet | Three tablets of Placebo tablet at a time, three times daily, 12 weeks administration |
Timeline
- Start date
- 2005-10-01
- Completion
- 2007-09-01
- First posted
- 2007-07-06
- Last updated
- 2026-01-06
- Results posted
- 2011-08-11
Source: ClinicalTrials.gov record NCT00497198. Inclusion in this directory is not an endorsement.